Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGF_" to "Category:VEGFR_") |
||
| Line 20: | Line 20: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]. | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]. | ||
| − | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] (as Cabometyx) for the treatment of advanced [[Renal_cancer|renal cell carcinoma]] in patients who have received prior [[:Category: | + | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] (as Cabometyx) for the treatment of advanced [[Renal_cancer|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. |
*12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cancer|renal cell carcinoma (RCC)]]. | *12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cancer|renal cell carcinoma (RCC)]]. | ||
Revision as of 22:21, 7 February 2018
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 11/29/2012: FDA approved (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC).
- 4/25/2016: FDA approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
- 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC).
Also known as
- Code names: XL184, XL-184
- Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)